# Survival outcomes with trastuzumab deruxtecan in HER2-positive vs. HER2-low breast cancer patients with brain metastases: a real-world cohort study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/survival-outcomes-with-trastuzumab-deruxtecan-in-her2-positive-vs-her2-low/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Vivek Podder,Zouina Sarfraz,Tulika Ranjan,Andrea McCracken,Charlie Hurmiz,Lydia Hodgson,Arun Maharaj,Reshma Mahtani,Manmeet S. Ahluwalia |
| Citations | 0 |
| DOI | 10.1038/s41598-026-50871-x |
| Fields | Medicine |
| Open Access | true |
| OA Status | gold |
| OA URL | https://www.nature.com/articles/s41598-026-50871-x_reference.pdf |
| OpenAlex ID | https://openalex.org/W7162575840 |
| PMID | 42203808 |
| Type | article |
| Year | 2026 |

## Paper authors

- [Lydia Hodgson](https://scholariq.org/researchers/lydia-hodgson/)

## Paper journal

- [Scientific Reports](https://scholariq.org/journals/scientific-reports/)

## Paper primary topic

- [Brain Metastases and Treatment](https://scholariq.org/topics/brain-metastases-and-treatment/)

## Paper topics

- [Brain Metastases and Treatment](https://scholariq.org/topics/brain-metastases-and-treatment/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.